14011-21-3Relevant articles and documents
BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS
-
Page/Page column 553, (2018/03/25)
Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
NITROGENATED HETEROCYCLIC COMPOUND
-
Paragraph 0650, (2015/03/28)
The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
Bicyclic pyridones as potent, efficacious and orally bioavailable thrombin inhibitors
Coburn, Craig A.,Rush, Diane M.,Williams, Peter D.,Homnick, Carl,Lyle, Elizabeth A.,Lewis, S. Dale,Lucas Jr., Bobby J.,Di Muzio-Mower, Jillian M.,Juliano, Marylou,Krueger, Julie A.,Vastag, Kari,Chen, I-Wu,Vacca, Joseph P.
, p. 1069 - 1072 (2007/10/03)
A new class of conformationally constrained thrombin inhibitors is described. These compounds contain a unique bicyclic pyridone scaffold which serves as a P3P2 dipeptide surrogate. The synthesis and antithrombotic activity of these inhibitors is reported. (C) 2000 Elsevier Science Ltd. All rights reserved.
